Article

Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits

Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodźki Str 6, 20-093 Lublin, Poland.
Life Sciences (Impact Factor: 2.3). 01/2004; 74(5):553-62. DOI: 10.1016/j.lfs.2003.03.004
Source: PubMed

ABSTRACT Impaired homeostasis under diabetic conditions is connected with the increased production of free radicals and deficiency of antioxidative systems. The aim of this study was to analyze the effect of new oral antidiabetic drug-pioglitazone on activity of antioxidant factors and lipid peroxidation in vivo. The liver and kidney of alloxan-induced diabetic rabbits were examined after 4 and 8 weeks of treatment. After 4 weeks of diabetes the superoxide dismutase (Cu,Zn-SOD) activity in the liver was diminished while the catalase (CAT) activity and the level of ascorbic acid (AA) were elevated in comparison with the control group. Pioglitazone treatment during 4 weeks decreased the catalase activity in relation to the control diabetic animals. After 8 weeks of diabetes the CAT activity in the liver was elevated in comparison with the control group. Pioglitazone treatment during 8 weeks decreased the CAT activity and the level of lipid peroxidation products (LPO), and increased the Cu,Zn-SOD activity in relation to control diabetic animals. After 4 weeks of diabetes in the kidney the Cu,Zn-SOD activity and the level of ascorbic acid (AA) were diminished while the CAT activity and the LPO level were elevated in comparison with the control group. Pioglitazone treatment during 4 weeks increased the AA and decreased the LPO levels in relation to non-treated diabetic animals. After 8 weeks of disease the Cu,Zn-SOD activity in the kidney was diminished in comparison with the control group. Pioglitazone during 8 weeks decreased the LPO level in relation to non-treated diabetic animals. This study shows that diabetic animals undergo an important oxidative stress, which is partially corrected by pioglitazone treatment.

0 Followers
 · 
43 Views
 · 
0 Downloads
  • Source
    • "In the current study, the PPAR-γ agonist, PIO, achieved protective effects against CP-induced hepatotoxicity, as evident by repairing hepatic pathological picture, recovering liver functional enzymes, and reversing oxidative stress and inflammatory process. Despite sporadic contradictory studies [20, 55], PIO has been reported to attenuate liver injury via recovering hepatic oxidant/antioxidant balance in several animal models, as it succeeded in repairing hepatic DNA damaged due to high fat diet in mice [56], abolishing hepatic oxidative stress in alloxan-induced diabetic rabbit [57], preventing lipopolysaccharide-induced liver injury [58], and recovering liver after ischemia/reperfusion in rats [23]. In humans, PIO was demonstrated to improve hepatic functional parameters in nonalcoholic fatty liver patients [59] and in nondiabetic patients suffering from metabolic syndrome [60]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatoprotective potential of peroxisome proliferator activator receptor (PPAR)- α and - γ agonists, fenofibrate (FEN), and pioglitazone (PIO), respectively, against cyclophosphamide (CP)-induced toxicity has been investigated in rat. FEN and PIO (150 and 10 mg/kg/day, resp.) were given orally for 4 weeks. In separate groups, CP (150 mg/kg, i.p.) was injected as a single dose 5 days before the end of experiment, with or without either PPAR agonist. CP induced hepatotoxicity, as it caused histopathological alterations, with increased serum alanine and aspartate transaminases, total bilirubin, albumin, alkaline phosphatase and lactate dehydrogenase. CP caused hepatic oxidative stress, indicated by decrease in tissue reduced glutathione, with increase in malondialdehyde and nitric oxide levels. CP also caused decrease in hepatic antioxidant enzyme levels, including catalase, superoxide dismutase, glutathione peroxidase, and glutathione S-transferase. Furthermore, CP increased serum and hepatic levels of the inflammatory marker tumor necrosis factor (TNF)- α , evaluated using ELISA. Preadministration of PIO, but not FEN, prior to CP challenge improved hepatic function and histology, and significantly reversed oxidative and inflammatory parameters. In conclusion, activation of PPAR- γ , but not PPAR- α , conferred protection against CP-induced hepatotoxicity, via activation of antioxidant and anti-inflammatory mechanisms, and may serve as supplement during CP chemotherapy.
    PPAR Research 04/2014; 2014(1):626319. DOI:10.1155/2014/626319 · 1.64 Impact Factor
  • Source
    • "Moreover, by suppressing the synthesis and release of monocyte chemoattractant protein 1 (MCP-1), glitazones can also limit chemotaxis and infiltration of inflammatory cells in the renal interstitium [35]. On the other hand, glitazones exert powerful anti-oxidant actions in experimental models, an effect largely independent from their interference with glucose metabolism [36]. Putative renoprotective mechanisms of glitazones include the interference with the renin-angiotensin system in the renal vasculature, reduced contractility of mesangial cells, and perhaps interference with albumin uptake in tubular cells [35]. "
    Nutrition Metabolism and Cardiovascular Diseases 03/2012; · 3.88 Impact Factor
  • Source
    • "Moreover, by suppressing the synthesis and release of monocyte chemoattractant protein 1 (MCP-1), glitazones can also limit chemotaxis and infiltration of inflammatory cells in the renal interstitium [35]. On the other hand, glitazones exert powerful anti-oxidant actions in experimental models, an effect largely independent from their interference with glucose metabolism [36]. Putative renoprotective mechanisms of glitazones include the interference with the renin-angiotensin system in the renal vasculature, reduced contractility of mesangial cells, and perhaps interference with albumin uptake in tubular cells [35]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glitazones rank now among the most used hypoglycemic agents in patients with type-2 diabetes. This systematic review focuses on the cardiovascular and renal outcomes in chronic kidney disease (CKD) patients treated with these drugs. Data from randomized clinical trials and a meta-analysis indicate that glitazones (particularly rosiglitazone) may increase the risk of myocardial infarction, heart failure and cardiovascular death in type-2 diabetics. Observational studies looking at survival and cardiovascular outcomes in diabetic patients with kidney failure show controversial results. Studies in experimental models and clinical studies suggest that glitazones may have favorable effects on renal disease progression, because these drugs coherently reduce urinary albumin excretion and proteinuria in diabetic and non-diabetic nephropathies. No clinical trial based on clinical end-points like kidney failure has until now tested the effect of glitazones on the evolution of chronic renal failure in these patients. Whether the use of glitazones has a positive or a negative impact upon major cardiovascular and renal outcomes in diabetic patients remains an open, unanswered question. Specific studies are needed to assess the efficacy and safety of glitazones in a high risk population like type-2 diabetics with chronic kidney disease.
    Nutrition, metabolism, and cardiovascular diseases: NMCD 03/2012; 22(3):167-75. DOI:10.1016/j.numecd.2011.11.005 · 3.88 Impact Factor
Show more